- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
EndoSonics to acquire Navius
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics access to the intravascular ultrasound-guided stenting market. EndoSonics has agreed to pay approximately $15.5 million in cash and EndoSonics common stock, in addition to royalties on future product sales. The deal was expected to close July 31.
The Rancho Cordova, CA, firm also announced last month an agreement in principle to partner with Fukuda Denshi, a Japanese medical products company. Fukuda has agreed to make an equity investment and R&D funding totaling $13 million in EndoSonics.
The agreements cut EndoSonics' final ties to Johnson & Johnson's Cordis division, the company's former distributor and therapeutic product partner. EndoSonics decided to terminate its relationship with Cordis when its product orders declined (SCAN 4/29/98).
In other EndoSonics news, the company reported second-quarter 1998 (end-June) net income of $1 million on revenue of $10 million, a 34% increase over the $751,000 net income on revenue of $7.1 million for the previous year's second quarter.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
